8-K: NextCure Files IND for LNCB74, an Antibody-Drug Conjugate Targeting B7-H4

NextCure has filed an Investigational New Drug application for LNCB74, an antibody-drug conjugate targeting B7-H4, with first-in-human trials expected in Q1 2025.

Summary

• NextCure has submitted an Investigational New Drug (IND) application for LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4.
• LNCB74 is designed to treat breast, endometrial, and ovarian cancers.
• The company expects to begin first-in-human (FIH) trials in Q1 2025.
• LNCB74 uses a differentiated glucuronidase cleavable linker for improved safety and efficacy.
• The company has completed GLP toxicology studies and GMP manufacturing for the Phase 1 trial.
• NextCure has approximately $75 million in cash on hand as of the end of Q3, providing a runway into the second half of 2026.

Sentiment

Score: 7

Explanation: The document is positive due to the IND filing and upcoming clinical trials, but tempered by the inherent risks of drug development and the company's history of losses.

Positives

• The IND filing for LNCB74 is a significant step forward for the company.
• The differentiated glucuronidase linker technology has the potential to improve safety and efficacy compared to other ADCs.
• The company has completed necessary preclinical studies and manufacturing for the Phase 1 trial.
• The company has a strong cash position of approximately $75 million, providing a runway into the second half of 2026.
• LNCB74 has shown potent anti-tumor activity in preclinical models.

Negatives

• The company has a limited operating history and no products approved for commercial sale.
• NextCure has a history of significant losses.
• The company will need to obtain additional financing in the future.

Risks

• The impacts of the COVID-19 pandemic could affect NextCure's business, including clinical trials.
• Positive results in preclinical studies may not predict the results of clinical trials.
• There are risks related to clinical development, marketing approval, and commercialization.
• The approach to the discovery and development of product candidates based on NextCure's discovery platform is unproven.
• The company is dependent on key personnel.

Future Outlook

The company anticipates initiating first-in-human trials for LNCB74 in Q1 2025 and is planning for Phase 1 dose escalation and expansion studies.

Management Comments

• The company will be engaging with members of the investment community, which may reference these presentation materials.

Industry Context

The development of LNCB74 places NextCure in competition with other companies developing ADCs targeting B7-H4, such as GSK, LegoChem, and others, in the rapidly growing field of antibody-drug conjugates for cancer treatment.

Comparison to Industry Standards

• Several companies are developing B7-H4 ADCs, including SGN-B7H4V, XMT-1660, HS-20089, AZD8205, and DB-1312/BG-C9074.
• These ADCs use different linkers and payloads, with some using val-cit cleavable linkers and others using protease cleavable linkers.
• NextCure's LNCB74 uses a glucuronidase cleavable linker, which is a differentiating factor.
• Clinical data from other B7-H4 ADCs show some promising results, including partial and complete responses in various cancers, but also some toxicities such as neutropenia and peripheral neuropathy.
• LNCB74 aims to improve safety and efficacy compared to these other ADCs through its unique linker technology.

Stakeholder Impact

• Shareholders may see potential value in the company's progress with LNCB74.
• Employees may be impacted by the progress of the clinical trials.
• Patients with breast, endometrial, and ovarian cancers may benefit from the development of LNCB74.

Next Steps

• Initiate first-in-human trials for LNCB74 in Q1 2025.
• Conduct Phase 1 dose escalation and expansion studies.
• Engage with the investment community.

Key Dates

Keywords

LNCB74, Antibody-drug conjugate, ADC, B7-H4, Cancer, Oncology, Clinical trials, IND, Glucuronidase linker, Drug development